Interstitial nephritis and mesalazine: Three new cases?;Nephrite interstitielle chronique et mesalazine: 3 nouveaux cas?

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 8-9, 1998, Pages 724-726

  Brouillard, Marc ^a   Gheerbrant, Jean Dominique ^a   Gheysens, Yves ^b   Fleury, Dominique ^c   Devred, Michel ^b   Hazzan, Marc ^d   Colombel, Jean Frédéric ^d  

^a CENTRE HOSPITALIER   (France)

^b CHU ^*  (France)

^c CENTRE HOSPITALIER DE VALENCIENNES   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Crohn's disease; Interstitial nephritis; Mesalazine; Renal insufficiency; Ulcerative colitis

Indexed keywords

CREATININE; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISONE; PREDNISONE ACETATE; SALAZOSULFAPYRIDINE; SILICON DIOXIDE; STEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; CROHN DISEASE; FEMALE; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; MALE; NEPHROTOXICITY; ULCERATIVE COLITIS; CHEMICALLY INDUCED DISORDER;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; MALE; MESALAMINE; NEPHRITIS, INTERSTITIAL;

EID: 0031726926     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Marteau P, Cellier C. Effets indésirables de l'acide 5-aminosalicylique. Gastroenterol Clin Biol 1997;21:377-86.
2. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazineassociated interstitial nephritis. Nephrol Dial Transplant 1996;11:614-21.
3. Witte T, Olbricht CJ, Koch KM. Interstitial nephritis associated with 5-aminosalicylic acid. Nephron 1994;67:481-2.
4. Garcia Diaz M, Nevado L, Berenguer A, Bureo JC, Bureo P, Saenz de Santamaria J. Insuficiencia renal aguda asociada a acido 5-aminosalicilico en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol 1995;18:18-21.
5. De Broe ME, Stolear JC, Nouwen EJ, Elseviers MM. 5-aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link ? Nephrol Dial Transplant 1997;12:1839-41.
6. Begaud B, Evreux JC, Jouglard J, Lagier G, Imputubilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Thérapie 1985;40:111-8.
7. Barbour VM, Williams PF. Nephrotic syndrome associated with sulfasalazine. Br Med J 1990;301:818.
8. Novis BH, Korzets Z, Chen P, Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J 1988;296:1442.
9. Wilcox GM, Reynolds JR, Galvanek EG. Nephrotoxicity associated with olsalazine. Am J Med 1996;100:238-40.
10. Manenti L, De Rosa A, Buzio C. Mesalazine-associaled interstitial nephritis: twice in the same patient. Nephrol Dial Transplant 1997;12:2031.
11. Thuluvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine induced interstitial nephritis. Gut 1994;35:1493-6.
12. Hanauer SB, Verst-Brasch C, Regalli G. Renal safety of long-term mesalazine therapy in inflammatory bowel disease (IBD) (abstract). Gastroenterology 1997;112 (suppl. 4):A991.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Schreiber S, Hamling J, Zehnter E, Howaldt S, Daerr W, Raedler A, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997;40:761-6.